CLI-06727AA1-03: Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease (clinicaltrialsregister.eu) - Jun 11, 2026 - P2/3 | N=40 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
New P2/3 trial • Cardiovascular • Heart Failure • Pediatrics
|